Behavioral effects of @entity1091 on presynaptic sites of catecholaminergic neurons in the XXXX .

@entity13557 @entity888 @entity19 @entity935 @entity3826 @entity2645 @entity1767 @entity1773 @entity1091
The effect of @entity1091 on locomotor activity in @entity19 was studied and an attempt was made to elucidate the neuronal mechanisms involved. @entity13557 (200 mg/kg, i.p.) administered acutely or daily for 7 days did not affect locomotor activity. A single injection of @entity3826 at a low dose of 0.25 mg/kg (i.p.) markedly decreased locomotor activity but repeated injection of the drug produced hyperlocomotion accompanied by sniffing. @entity888 (1 mg/kg, i.p.), @entity1767 (0.02 mg/kg, i.p.), thyrotropin releasing hormone (5 mg/kg, i.p.) or @entity3826 (1 mg/kg, i.p.) exerted a biphasic action in locomotor activity, i.e. an initial increase and subsequent decrease. This initial hyperlocomotion induced by these drugs, except for @entity3826 , was inhibited by @entity1091 (200 mg/kg, i.p. X 1) or a low dose of @entity3826 (0.25 mg/kg, i.p. X 1). The subsequent hypolocomotion was also attenuated by @entity1091 , but not by @entity3826 . @entity2645 (10 mg/kg, i.p.) increased the hyperlocomotion induced by @entity888 . The inhibitory effect of @entity1773 (5 mg/kg, i.p.) on locomotor activity was attenuated after repeated treatment with @entity1091 (200 mg/kg, i.p. X 7) or @entity2645 (10 mg/kg, i.p. X 7). The results suggest that @entity1091 may inhibit dopaminergic neuron activities, probably not through an activation of presynaptic @entity935 autoreceptors.
